82 related articles for article (PubMed ID: 17657224)
1. A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer.
Rabin N; Kyriakou C; Coulton L; Gallagher OM; Buckle C; Benjamin R; Singh N; Glassford J; Otsuki T; Nathwani AC; Croucher PI; Yong KL
Leukemia; 2007 Oct; 21(10):2181-91. PubMed ID: 17657224
[TBL] [Abstract][Full Text] [Related]
2. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
Sordillo EM; Pearse RN
Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
[TBL] [Abstract][Full Text] [Related]
3. Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts.
Doran PM; Turner RT; Chen D; Facteau SM; Ludvigson JM; Khosla S; Riggs BL; Russell SJ
Exp Hematol; 2004 Apr; 32(4):351-9. PubMed ID: 15050745
[TBL] [Abstract][Full Text] [Related]
4. Intra-bone marrow cotransplantation of donor mesenchymal stem cells in pig-to-NOD/SCID mouse bone marrow transplantation facilitates short-term xenogeneic hematopoietic engraftment.
Eguchi H; Kuroiwa Y; Matsui A; Sada M; Nagaya N; Kawano S
Transplant Proc; 2008 Mar; 40(2):574-7. PubMed ID: 18374132
[TBL] [Abstract][Full Text] [Related]
5. NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.
Lawson MA; Paton-Hough JM; Evans HR; Walker RE; Harris W; Ratnabalan D; Snowden JA; Chantry AD
PLoS One; 2015; 10(3):e0119546. PubMed ID: 25768011
[TBL] [Abstract][Full Text] [Related]
6. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
[TBL] [Abstract][Full Text] [Related]
7. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells.
Yata K; Yaccoby S
Leukemia; 2004 Nov; 18(11):1891-7. PubMed ID: 15385929
[TBL] [Abstract][Full Text] [Related]
8. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium.
Atkins GJ; Kostakis P; Welldon KJ; Vincent C; Findlay DM; Zannettino AC
J Cell Physiol; 2005 Jun; 203(3):573-82. PubMed ID: 15573398
[TBL] [Abstract][Full Text] [Related]
9. Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging mice.
Shahnazari M; Dwyer D; Chu V; Asuncion F; Stolina M; Ominsky M; Kostenuik P; Halloran B
Bone; 2012 Mar; 50(3):628-37. PubMed ID: 22154841
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo.
Xu S; Menu E; De Becker A; Van Camp B; Vanderkerken K; Van Riet I
Stem Cells; 2012 Feb; 30(2):266-79. PubMed ID: 22102554
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Croucher PI; Shipman CM; Van Camp B; Vanderkerken K
Cancer; 2003 Feb; 97(3 Suppl):818-24. PubMed ID: 12548581
[TBL] [Abstract][Full Text] [Related]
12. Human mesenchymal stem cells (hMSCs) expressing truncated soluble vascular endothelial growth factor receptor (tsFlk-1) following lentiviral-mediated gene transfer inhibit growth of Burkitt's lymphoma in a murine model.
Kyriakou CA; Yong KL; Benjamin R; Pizzey A; Dogan A; Singh N; Davidoff AM; Nathwani AC
J Gene Med; 2006 Mar; 8(3):253-64. PubMed ID: 16288493
[TBL] [Abstract][Full Text] [Related]
13. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
14. Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
Buckle CH; De Leenheer E; Lawson MA; Yong K; Rabin N; Perry M; Vanderkerken K; Croucher PI
PLoS One; 2012; 7(8):e41127. PubMed ID: 22952578
[TBL] [Abstract][Full Text] [Related]
15. Imbalance of the osteoprotegerin/RANKL ratio in bone marrow microenvironment after allogeneic hemopoietic stem cell transplantation.
Ricci P; Tauchmanova L; Risitano AM; Carella C; Mazziotti G; Lombardi G; Colao A; Rotoli B; Selleri C
Transplantation; 2006 Dec; 82(11):1449-56. PubMed ID: 17164716
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin and osteoprotegerin ligand expression during human marrow stromal cell differentiation and their effect on osteoclast formation.
Yang L; Hai Y; Zhou JL
Chin Med J (Engl); 2011 Jul; 124(13):2033-7. PubMed ID: 22088466
[TBL] [Abstract][Full Text] [Related]
17. Factors that influence short-term homing of human bone marrow-derived mesenchymal stem cells in a xenogeneic animal model.
Kyriakou C; Rabin N; Pizzey A; Nathwani A; Yong K
Haematologica; 2008 Oct; 93(10):1457-65. PubMed ID: 18728032
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.
Standal T; Hjorth-Hansen H; Rasmussen T; Dahl IM; Lenhoff S; Brenne AT; Seidel C; Baykov V; Waage A; Børset M; Sundan A; Hjertner O
Haematologica; 2004 Feb; 89(2):174-82. PubMed ID: 15003892
[TBL] [Abstract][Full Text] [Related]
19. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
Vanderkerken K; De Leenheer E; Shipman C; Asosingh K; Willems A; Van Camp B; Croucher P
Cancer Res; 2003 Jan; 63(2):287-9. PubMed ID: 12543775
[TBL] [Abstract][Full Text] [Related]
20. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
